Compare STRIDES PHARMA SCIENCE with Orchid Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES PHARMA SCIENCE vs ORCHID PHARMA - Comparison Results

STRIDES PHARMA SCIENCE     Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

ORCHID PHARMA 
   Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES PHARMA SCIENCE ORCHID PHARMA STRIDES PHARMA SCIENCE/
ORCHID PHARMA
 
P/E (TTM) x 44.5 -130.1 - View Chart
P/BV x 2.1 37.3 5.6% View Chart
Dividend Yield % 0.2 0.0 -  

Financials

 STRIDES PHARMA SCIENCE   ORCHID PHARMA
EQUITY SHARE DATA
    STRIDES PHARMA SCIENCE
Mar-18
ORCHID PHARMA
Sep-13
STRIDES PHARMA SCIENCE/
ORCHID PHARMA
5-Yr Chart
Click to enlarge
High Rs1,147194 591.2%   
Low Rs64235 1,834.3%   
Sales per share (Unadj.) Rs317.2276.5 114.8%  
Earnings per share (Unadj.) Rs7.8-79.2 -9.9%  
Cash flow per share (Unadj.) Rs25.1-43.5 -57.7%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.20-  
Book value per share (Unadj.) Rs274.353.9 508.5%  
Shares outstanding (eoy) m89.5070.45 127.0%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x2.80.4 680.8%   
Avg P/E ratio x114.0-1.4 -7,888.2%  
P/CF ratio (eoy) x35.7-2.6 -1,354.8%  
Price / Book Value ratio x3.32.1 153.6%  
Dividend payout %25.50-   
Avg Mkt Cap Rs m80,0588,067 992.5%   
No. of employees `0002.52.8 89.5%   
Total wages/salary Rs m4,3412,527 171.8%   
Avg. sales/employee Rs Th11,325.86,956.1 162.8%   
Avg. wages/employee Rs Th1,731.4902.5 191.8%   
Avg. net profit/employee Rs Th280.1-1,993.0 -14.1%   
INCOME DATA
Net Sales Rs m28,39419,477 145.8%  
Other income Rs m941407 231.0%   
Total revenues Rs m29,33419,884 147.5%   
Gross profit Rs m3,9651,103 359.6%  
Depreciation Rs m1,5402,519 61.1%   
Interest Rs m1,9625,227 37.5%   
Profit before tax Rs m1,403-6,236 -22.5%   
Minority Interest Rs m020 0.0%   
Prior Period Items Rs m-1680-   
Extraordinary Inc (Exp) Rs m-436511 -85.3%   
Tax Rs m97-125 -77.7%   
Profit after tax Rs m702-5,580 -12.6%  
Gross profit margin %14.05.7 246.7%  
Effective tax rate %6.92.0 345.4%   
Net profit margin %2.5-28.7 -8.6%  
BALANCE SHEET DATA
Current assets Rs m24,83611,014 225.5%   
Current liabilities Rs m18,99332,060 59.2%   
Net working cap to sales %20.6-108.1 -19.0%  
Current ratio x1.30.3 380.6%  
Inventory Days Days7195 74.8%  
Debtors Days Days11334 338.0%  
Net fixed assets Rs m34,28929,440 116.5%   
Share capital Rs m895705 127.0%   
"Free" reserves Rs m23,6512,043 1,157.9%   
Net worth Rs m24,5463,800 646.0%   
Long term debt Rs m15,5139,018 172.0%   
Total assets Rs m65,43746,510 140.7%  
Interest coverage x1.7-0.2 -888.1%   
Debt to equity ratio x0.62.4 26.6%  
Sales to assets ratio x0.40.4 103.6%   
Return on assets %4.1-0.8 -535.7%  
Return on equity %2.9-146.9 -1.9%  
Return on capital %6.9-3.7 -184.6%  
Exports to sales %037.9 0.0%   
Imports to sales %022.6 0.0%   
Exports (fob) Rs mNA7,378 0.0%   
Imports (cif) Rs mNA4,406 0.0%   
Fx inflow Rs m15,6977,513 208.9%   
Fx outflow Rs m7355,649 13.0%   
Net fx Rs m14,9621,865 802.5%   
CASH FLOW
From Operations Rs m1,8711,682 111.2%  
From Investments Rs m5,826-9,860 -59.1%  
From Financial Activity Rs m-10,1576,644 -152.9%  
Net Cashflow Rs m-2,615-1,535 170.4%  

Share Holding

Indian Promoters % 27.7 32.3 85.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 37.8 4.6 821.7%  
FIIs % 8.6 3.3 260.6%  
ADR/GDR % 0.0 4.6 -  
Free float % 25.9 55.3 46.8%  
Shareholders   56,241 84,811 66.3%  
Pledged promoter(s) holding % 0.0 54.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES PHARMA SCIENCE With:   CIPLA  PIRAMAL ENTERPRISES  NATCO PHARMA  NEULAND LABS  PFIZER  

Compare STRIDES PHARMA SCIENCE With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 272 Points Higher; Hindalco, Hero MotoCorp & Wipro Surge Over 4%(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended higher.

Related Views on News

STRIDES PHARMA SCIENCE Announces Quarterly Results (3QFY21); Net Profit Down 46.4% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 621 m (down 46.4% YoY). Sales on the other hand came in at Rs 8 bn (up 13.6% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY21); Net Profit Up 184.5% (Quarterly Result Update)

Aug 20, 2020 | Updated on Aug 20, 2020

For the quarter ended June 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 1 bn (up 184.5% YoY). Sales on the other hand came in at Rs 8 bn (up 14.0% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY20); Net Profit Up 2778.7% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 2 bn (up 2778.7% YoY). Sales on the other hand came in at Rs 7 bn (down 2.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (4QFY19); Net Profit Up 7919.8% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 650 m (up 7919.8% YoY). Sales on the other hand came in at Rs 8 bn (up 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

More Views on News

Most Popular

Power Grid's InvIT IPO: Key Points to Consider(Company Info)

Apr 23, 2021

In this article, we discuss the key reasons why the stock of Power Grid was in focus today.

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

This Fund Manager Has Taken the World by Storm. Will You Invest With Her?(Profit Hunter)

Apr 26, 2021

Should you invest with this Rockstar fund manager who has outperformed in a big way?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES PHARMA SCIENCE SHARE PRICE


May 6, 2021 (Close)

TRACK STRIDES PHARMA SCIENCE

  • Track your investment in STRIDES PHARMA SCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES PHARMA SCIENCE

STRIDES PHARMA SCIENCE 5-YR ANALYSIS

COMPARE STRIDES PHARMA SCIENCE WITH

MARKET STATS